Abstract Group B streptococci (GBS) are a leading cause of infectious neonatal morbidity and mortality. Timely and accurate identification of colonized pregnant women is imperative to implement intrapartum antibioprophylaxis (IAP) to reduce the risk of early neonatal sepsis. Current guidelines recommend screening for GBS carriage with vaginal-rectal cultures. However, cultures require 24-72 h, thus precluding their use for intrapartum screening and these are only performed at 35-37 weeks gestation. New rapid molecular-based tests can detect GBS within hours. They have the potential to be used intrapartum and to allow for selective IAP in women carrying GBS. An advantage is that they can sometimes be performed by non-laboratory staff in the labor suite, thus avoiding delays in sample transfers to the microbiology laboratory. Another possible use of molecular-based assays is for the diagnosis of neonatal sepsis, where tests with a short turnaround time and high sensitivity and specificity are crucial. In this situation, the detection of microorganisms once antibiotic therapy has already been started is important, as treatment is started immediately once sepsis is suspected without waiting for microbiological confirmation. In this article, we discuss the state-of-the-art molecular-based tests available for GBS screening during pregnancy, as well as their implications for IAP for the diagnosis and prevention of neonatal sepsis.
Introduction
Group B streptococci (GBS) are one of the leading causes of neonatal and maternal infectious complications [1, 2] . Neonatal infection can result in neonatal death or severe morbidity, such as septicemia, pneumonia, or meningitis. Infections occurring within the first week of life in newborns are called early-onset disease (EOD). Late-onset infections (LOD) occur after 1 week of age (from day 7 to day 89). There is evidence that intrapartum antibiotic prophylaxis (IAP) for colonized pregnant women decreases the risk of vertical transmission of GBS, as well as the risk of EOD [3] . GBS culture in broth enrichment of vaginalrectal swabs remains the reference standard for the detection of GBS colonization, but it requires 24-72 h, thus precluding its use for intrapartum screening. Several nationwide organizations, such as the US Centers for Disease Control and Prevention (CDC) and the Swiss Society of Obstetrics and Gynecology, currently recommend antenatal screening with vaginal-rectal cultures and selective IAP administration to GBS-positive women [4] . Adherence to these recommendations has dramatically decreased the incidence of GBS EOD [5, 6] .
Nevertheless, several studies have shown a low sensitivity of antenatal GBS cultures to detect colonization during labor [7] [8] [9] . Cases of EOD in infants born at term have occurred among mothers with negative antenatal GBS culture results and it has been reported that at least 10 % of this group of women turned positive at labor [10] . Based on current guidelines, these women do not receive IAP and their neonates are at risk of EOD [11] . Neonates born preterm are at the highest risk of EOD and their mothers receive IAP based on the risk-factor strategy, irrespective of their colonization status. However, in a study in Finland, only 35 % of newborns with EOD had risk factors [12] , thus demonstrating that this strategy is clearly not effective. Conversely, because colonization with GBS concerns fewer than 20 % of pregnant women, there is a risk of overtreatment when using the risk-factor strategy. The widespread use of antibiotics is associated with maternal anaphylaxis [13] and the selection of resistant strains of Escherichia coli, now increasingly reported in neonatal sepsis [14] [15] [16] .
Rapid GBS detection tests have the potential to overcome all of the above-mentioned limitations [17, 18] . If performed during labor and if rapid and sensitive enough, they could obviate the need for prenatal screening and reduce the use of antibiotic prophylaxis in pregnant women who are not colonized. In this article, we review the existing rapid and/or molecular-based tests for GBS detection and for the identification of pathogens in neonatal sepsis. We also discuss their advantages and inconveniences when compared with currently recommended culture techniques. To write this review, we searched Pubmed with the following key words: Group B Streptococcus, carriage, molecular-based tests, PCR, pregnancy, intrapartum, screening, diagnosis, and neonatal sepsis.
Molecular-Based Diagnosis of GBS Colonization
Screening for the Prevention of Neonatal Sepsis
In the 1980s, there were several attempts at developing rapid non-molecular diagnostic tests for GBS screening [19] [20] [21] . However, to be useful in the intrapartum setting, rapid tests should provide accurate results within 1 h, because IAP should be administered at least 4 h before delivery to be effective [22] . Optical immunoassays performed better than other tests targeting GBS antigens with results available in less than 1 h, but they were shown to be inaccurate and not reproducible enough to be used to determine GBS colonization [23] . Supporters of antigenic detection tests used to argue that they had better sensitivity in the context of heavy GBS colonization and that it is precisely in these situations where the risk of EOD is higher [24] . However, the US Food and Drug Administration (FDA) emitted an alert warning of the risk of using these antigenic tests because of too many false-positive and false-negative results [25] . In the latest CDC guidelines, tests targeting GBS antigens are not considered as being sufficiently sensitive to be used for prenatal screening [4] . Therefore, direct antigenic tests have been abandoned. However, the need for rapid detection of GBS has been a constant drive for the development of culture-independent tests. Molecular-based tests for the detection of DNA have since been developed, and are now competing with culture for the detection of GBS carriage in pregnant women.
DNA Hybridization Methods
DNA hybridization tests target the GBS ribosomal RNA. One of the most popular probe hybridization systems for GBS is the AccuProbe Ò Group B Streptococcus Culture Identification test (Gen-Probe, San Diego, CA, USA). In their review on rapid tests for the detection of GBS colonization in laboring women, Honest et al. [26] concluded that DNA hybridization requires too much time to be performed intrapartum. Indeed, without a pre-enrichment culture of several hours (18-24 h), its sensitivity is poor [27] . Therefore, they cannot be used for direct detection and identification of GBS from vaginal-rectal swabs of women in labor.
Nucleid Acid Amplification Tests

Polymerase Chain Reaction
Polymerase chain reaction (PCR) offers a great potential for rapid, highly sensitive, and specific detection of various infectious agents directly from clinical samples. Several PCR assays targeting different genes for the specific detection of GBS have been developed. The first PCR assay developed was conventional PCR followed by gel electrophoresis and targeted the gene coding for the Christie-Atkins-Munch-Petersen factor (cfb gene) [28] .
Other genes, such as the scpB gene, encoding for the C5a peptidase were targeted for the detection of GBS, but did not reach commercialization, probably because of complexity and promiscuity with scpA and scpG genes [29] .
Conventional PCR is timeconsuming (around 6 h), requires expertise, and is not appropriate for intrapartum detection of GBS colonization. Bergeron et al., who identified the cfb gene as a convenient target, developed a realtime PCR assay and validated its potential use in 2000. In this study, they identified GBS in vaginal-rectal swabs in less than 45 min with [95 % sensitivity and specificity when compared with culture on a selective broth medium [17] . Infectio Diagnostic (IDI, Sainte-Foy, QC, Canada) TM assay demonstrated a sensitivity of 94 % and a specificity of 96 % compared with intrapartum cultures. It was revealed to be more sensitive than an antenatal reference culture or a risk-based strategy to predict GBS colonization status at delivery [30] . The superiority of the intrapartum molecular detection of GBS when compared with antenatal culture was confirmed by a Canadian group [31] . In their study, the sensitivity of the IDI-Strep B TM assay was 90.7 %, whereas it was only 84.3 % with an antenatal culture. Moreover, results of the intrapartum PCR were available more than 4 h before delivery in 81 % of the cases, allowing for effective IAP [22] . Another study from the UK [32] , compared the Cepheid Smart GBS Ò Kit and SmartCycler Ò System on vaginal and rectal swabs with intrapartum culture. Combined swabs were 84 % sensitive, with rectal swabbing being more sensitive than vaginal swabbing, but less well accepted.
Real-time PCR is rapid and sensitive enough for the intrapartum detection of GBS colonization, but it still requires the use of specialized technicians in the microbiology laboratory. Cepheid's GeneXpert Ò system has been developed to minimize the need for specialized technicians. It is based on a closed cartridge that contains all reagents required for extraction, amplification, and detection. Xpert Ò GBS targets the same gene as IDI-Strep B TM and provides even better results than the latter assay [18] . In 2009, a French study showed that the intrapartum test with Xpert Ò GBS was highly sensitive and specific and provided a much higher positive predictive value for intrapartum GBS colonization (97.8 %) than antenatal cultures (58.3 %) [7] . These results should be interpreted with caution, because antenatal cultures were not performed as recommended to reach optimal sensitivity, thus favoring the sensitivity of PCR and lowering the positive predictive value of antenatal cultures. Indeed, no enrichment (Todd-Hewitt) broth was used and vaginal instead of recto-vaginal swabs were performed. Finally, in this study, Xpert Ò GBS was performed in the laboratory by specialized personnel and not as a point-of-care (POC) assay by midwives, once again favoring the success of this molecular method. Another advantage of this test is that in the context of rupture of the membranes, the Xpert Ò GBS was at least as sensitive as culture when both are performed on amniotic fluid [33] . A small study performed in the USA compared the Xpert Ò GBS with antenatal culture, using intrapartum culture as a gold standard. Once again, the PCR-based approach was more sensitive (95.8 %) than antenatal culture (83.3 %). However, the specificity of the molecular assay was surprisingly low in this study (64.5 %), possibly owing to surface contamination [34] .
Point of Care Detection Nucleic-Acid Based Assays for Screening of GBS Colonization
In most settings, the microbiology laboratory is not open 24 hours a day/7 days a week and transport time to the laboratory further delays the time to a result. Thus, a strategy based on 'real-time' molecular detection cannot be established to determine the need for IAP. POC testing has been described as a potentially cost-effective solution in this type of setting. It is particularly interesting for obstetrics where the important and relevant pathogens (GBS, Listeria spp.) have predictable antimicrobial susceptibilities and their detection is frequently clinically meaningful [35] . A PCR-based POC test, such as Xpert Ò GBS, can be performed by non-laboratory personnel (i.e., midwives) in the labor suites [36] . It has been shown to be at least as accurate as the antenatal culture-based screening with the advantage of identifying those women who are really carrying GBS during labor and allowing for targeted IAP. Moreover, it allows for screening pregnant women whose babies are at higher risk for neonatal sepsis, such as those delivering preterm or not followed during pregnancy [36] . However, because of the reimbursement system used in most countries (diagnostic related groups), hospitals are not inclined to add laboratory examinations to in-hospital treatments, and it is difficult to convince hospital administrators to invest in strategies to spare antibiotic use if their application is more costly than the price of the antibiotic itself. Indeed, as shown by Kaambwa [37] , the most costeffective method for the prevention of GBS neonatal sepsis is ''treat all'' (routine untargeted IAP to all). However, this attitude leads to unneeded antibiotic treatment for many pregnant mothers, with associated side effects for the mother and child. For the moment, the second best approach in terms of cost effectiveness is to base IAP on antenatal cultures [37] . This is, however, likely to change in the next few years. For example, a group from Paris studied the cost of providing PCR at the labor suite for GBS carriage [38] . They showed that the PCR strategy is cost neutral compared with the antenatal culture strategy if the cost of treating GBS-infected newborns is taken into account, with the benefit of decreasing the amount of GBS sepsis.
In our maternity unit in the university hospitals of Geneva, we perform antenatal GBS culture at 35-37 weeks and keep in-labor GBS rapid PCR for those women delivering preterm, not followed or not screened by their gynecologists. This policy allows for the protection of most delivering women from GBS neonatal sepsis, with little increase in costs.
Detection of GBS and Macrolide Resistance Genes by PCR
A problem of rapid GBS PCR assays is that they do not provide antimicrobial susceptibility testing (AST). There have been successful attempts at designing a multiplex PCR that detect GBS and its resistance genes to erythromycin and clindamycin on GBS colonies [39, 40] . Nevertheless, the multiplex PCR failed to detect GBS and its AST directly from vaginal-rectal specimens [41] . GBS remains uniformly sensitive to penicillin and cefazolin, and the need for AST concerns only patients with documented serious allergic reactions to penicillin. There are very limited data on the ability of clindamycin, erythromycin, or vancomycin to reach bactericidal levels in the amniotic fluid. Therefore, in their recommendations, the Committee on Infectious Diseases and the Committee on Fetus and Newborn state that a ''duration of IAP shorter than 4 h and all other regimens, including clindamycin and vancomycin, are considered to be inadequate prophylaxis for infants because of lack of data regarding efficacy and limited data regarding favorable pharmacokinetics [22] . No clinical trial has evaluated the efficacy of non-beta-lactam regimens for IAP in women with serious penicillin allergy''. Moreover, resistance to clindamycin and erythromycin is increasing [4, 42] . In a recent study of our group [43] , the rate of resistance to clindamycin and erythromycin was 28 % and 30 %, respectively. In some US hospitals, it has even reached 38 % and 50 %, respectively [44] . Despite this, in an evaluation of the implementation of the CDC guidelines in the USA, AST was rarely performed among women receiving clindamycin for prophylaxis [5] . Moreover, only 13.8 % of penicillin-allergic women who were not at high risk for anaphylaxis received cefazolin [5] . The most effective means for GBS prevention is probably the choice of a molecular strategy to detect intrapartum GBS colonization and to order antenatal cultures with AST for women at high-risk for anaphylaxis with penicillin derivatives.
Molecular Diagnosis of Neonatal Sepsis
GBS is a frequent cause of early-onset sepsis (EOS) affecting mostly term neonates. In preterm newborns, E. coli is the most frequent agent of EOS [45] . However, many other bacteria have been recovered in infants with sepsis, such as Staphylococci spp., Streptococci spp., Listeria monocytogenes, and Haemophilus influenza. The economic and ecologic cost of starting empiric intravenous antibiotics when suspecting EOS is extremely high. For example, in the UK, 10-12 % of all newborns are screened for EOS [46] . Because of the high mortality linked with EOS, antibiotics are rapidly introduced, sometimes even before culture, the latter becoming less sensitive. In this context, molecular detection of the pathogen could be very useful, because it should increase sensitivity and rapidity of the identification of pathogens, permitting the cessation of treatment of suspected EOS at 48 h if the 'septic screen' is negative [47] .
In a recent article, Tudela et al. proposed that EOS precedes birth [48] . Within this logic, we can expect that a newborn already carries a relatively high burden of the infectious agent when sepsis is clinically detected, which should favor the effectiveness of molecular identification of the pathogen. However, the principal difficulty resides in the fact that the main specimen available to determine the agent of sepsis in neonates is whole blood, which contains much more human than bacterial DNA. In neonatology, there is a supplementary challenge linked with the small amount of blood that can be drawn, because for culture as for molecular identification of bacteria, the more blood, the better the sensitivity. Different molecular approaches have been studied to improve the rapidity and the yield of bacterial detection in neonatal sepsis. It is crucial to differentiate which of these techniques are promising when performed directly on whole blood, or with a pre-enrichment phase, or on positive blood culture vials. Obviously, it is much easier to detect bacterial DNA in a positive blood culture (containing [1-6 cfu/ml) than on whole blood (containing 1-100 cfu/ ml), but the culture step is time consuming.
Detection of Pathogens in Positive Blood Culture
Several studies combining a multiplex PCR with different types of identification of amplicons have shown good correlation with cultures [49] [50] [51] . However, these expensive amplification techniques will probably not be used when starting from positive blood culture bottles. Indeed, growth in blood culture bottles provides sufficiently large amounts of bacteria for identification without molecular amplification, such as the use of fluorescent probes (fluorescence in situ hybridization) [52] or the bacterial identification by MALDI-TOF mass spectrometry (MS) [53] . MALDI-TOF MS has revolutionized clinical microbiology by allowing a rapid, accurate, and cheap identification of bacteria, including GBS [54] . In a recent study on 212 positive blood vials, MALDI-TOF MS yielded a good spectrum for 80 % of vials, with an accurate bacterial characterization of [95 % [55] .
Molecular Detection of Pathogens after a Preenrichment Phase
Jordan et al. [56] studied this strategy among 1,233 neonates evaluated for EOD. The culture positivity rate was 1.5 %. Pre-enrichment whole blood was incubated in tryptic soy broth for 5 h before extraction and amplification. 16S rDNA PCR failed to detect 10 of 17 cultureproven neonatal sepsis cases. This poor sensitivity condemns the use of pre-enrichment to improve the molecular diagnosis of EOD and LOD.
PCR on Whole Blood and Other Sterile Fluids of Septic Neonates
The diagnosis of neonatal sepsis cannot be based on clinical symptoms and signs that are not specific [57] . Positive culture of blood or other sterile fluid such as cerebrospinal fluid (CSF) is needed to establish definitively this diagnosis. However, the small volume of sample available and the use of IAP compromise the sensitivity of cultures. There is hope that molecular diagnostics could overcome these limitations and improve the diagnosis of neonatal sepsis. Different types of PCR, such as broad-range PCR, multiplex real-time PCR, and specific PCR, have been studied for the detection of pathogens in neonatal sepsis. Specific real-time PCR targeting GBS can be used on clinical specimens to detect EOS due to GBS. In a study on 110 blood culture-negative cases of probable neonatal sepsis [58] , colleagues from the Health Protection Agency in London have shown that a specific real-time PCR targeting the cylB gene of S. agalactiae was positive on 16/75 CSF (21 %) and 2/35 EDTA blood samples (6 %). Based on this study, we could expect the PCR to be more sensitive than culture. However, cases with positive blood cultures have not been tested by PCR, a step needed to determine clearly the sensitivity of PCR compared with blood cultures. Moreover, the authors could not confirm if the CSF positive by PCR was also positive by culture. This could explain the striking difference between the results in EDTA blood and in CSF.
Even if GBS accounts for up to 50 % of the cases of EOS, other pathogens can be implicated, especially when confronted with LOS. Broad-range PCR is crucial to detect pathogens when we do not know which one we are looking for. It is important to reiterate that broad-range bacterial PCR is typically less sensitive than a target-specific PCR. Yet, a Swedish study evaluated the potential benefits of using a broad-range real-time PCR approach [59] . Compared with blood cultures, the sensitivity was 79 %, thus meaning bacteremia could not be excluded when the PCR was negative. The positive predictive value of their broadrange PCR was only 59 %, but the specificity was 90 % and several clinical cases of neonatal sepsis could be confirmed by the molecular technique with negative cultures. Jordan et al. developed a real-time PCR targeting the 16S rRNA with a turnaround time of less than 5 h, which showed a good analytical sensitivity for the detection of pathogens in the blood of infants evaluated for EOS [60] .
In a recent study [57] , Pammi et al. performed a review of the literature on the molecular diagnosis of neonatal sepsis. Their conclusion was that the molecular diagnosis of EOS or LOS in newborns cannot yet replace culture, essentially because of a lack of sensitivity. However, molecular-based tests could be used in parallel to culture, essentially to reduce the time for pathogen identification. However, several studies on the use of a commercial, multiplex real-time PCR (SeptiFast, Roche Diagnostics GmbH, Basel, Switzerland) has shown better results than culture for the identification of the microbiologic diagnosis of neonatal sepsis. In a small study on 34 infants with suspected cases of LOS [61] , 7/7 etiologic agents of definitive neonatal sepsis were identified by the multiplex PCR, whereas only 3/7 were detected by culture. In a collective of 46 preterm infants with suspected neonatal sepsis [62] , SeptiFast (Roche Diagnostics GmbH, Basel, Switzerland) multiplex real-time PCR was more sensitive than culture (90 % vs. 71 %), but less specific (80 % vs. 100 %) because of 5/21 non-infected patients with positive PCR for coagulase-negative staphylococci.
Molecular-based tests cannot outrun culture, but are progressing rapidly for the diagnosis of neonatal sepsis and are now already complementary to culture. To compete seriously with culture, they would need to have an excellent negative predictive value and a high specificity.
Point of Care Test for Neonatal Sepsis
To improve patient care, POC tests should be reliable, robust, rapid (less than 1 h), easy to handle (non-laboratory staff), not require pre-test sample preparation, and be easy to interpret [63] . At present, such a test does not exist for the rapid diagnosis of EOS, but will most probably be part of routine clinical care in10 years from now.
Conclusions
Molecular-based tests for the detection of GBS are highly sensitive and specific. They can also be used as POC testing performed by non-laboratory staff and for some techniques the results are available in less than 1 h. This allows for the correct identification of women carrying GBS during labor and for screening pregnant women whose babies are at a higher risk for neonatal sepsis. For pregnancy screening and prevention of GBS EOS, rapid PCR performed during labor is probably the best strategy. For the diagnosis of neonatal sepsis, molecular-based tests cannot yet replace culture, mostly because of a lack of sensitivity. Currently, they could be used in parallel to culture to speed up the time to pathogen identification. However, there is a rapid improvement of the molecular diagnosis of neonatal sepsis, with a clear potential to compete favorably with culture in the next 10 years.
